CXCR4 and peripheral neuropathy: To our knowledge, this is the first study to demonstrate antinociceptive efficacy of a CB2-selective agonist in the cisplatin model and the first to evaluate a potential role for CXCR4 signaling in contributing to mechanisms of chemotherapy-induced peripheral neuropathy.